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ABSTRACT 
A reversed-phase high performance liquid chromatography (RP-HPLC) method was developed and validated for the estimation of 
esomeprazole in bulk and tablet dosage forms. The separation was achieved on Thermo C18 analytical column (250 mm × 4.6 mm i.d., 5.0 μm) 
using acetonitrile and methanol in the ratio 50:50 v/v as mobile phase and at a flow rate of 1.0 ml/min. Detection was carried out using a UV 
detector at 300nm. The total chromatographic analysis time per sample was about 8.0min with esomeprazole eluting at retention time of about 
6.863±0.3 min. The method was validated for accuracy, precision, specificity, linearity and sensitivity. Validation studies demonstrated that this 
HPLC method is simple, specific, rapid, reliable and reproducible. The standard curve was linear over the concentration range of 5-25μg/ml 
with r2 close to one (0.999). The limit of detection (LOD) and limit of quantitation (LOQ) obtained for esomeprazole were 0.100μg/ml and 
0.314μg/ml respectively. The developed and validated method was successfully applied for the quantitative analysis of ESOMZ 20 Tablet. The 
high recovery and low relative standard deviation confirm the suitability of the proposed method for the determination of esomeprazole in 
tablets dosage form. 
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INTRODUCTION 
Esomeprazole magnesium trihydrate1 (ESO), bis(5-methoxy-
2-[(S)- [(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] 
sulfinyl]-1-H-benzimidazole-1- yl)magnesium trihydrate 
[Figure 1], is a compound that inhibits gastric acid secretion. 
ESO is cost-effective in the treatment of gastric oesophageal 
reflux diseases. ESO is the S-isomer of omeprazole, the first 
single optical isomer proton pump inhibitor, generally 
provides better acid control than current racemic proton 
pump inhibitors and has a favorable pharmacokinetic profile 
relative to omeprazole2. Several methods have been 
employed for the estimation of ESO alone and combination 
with other drugs such as UV and RP-HPLC methods3-11. But 
there is no simple and easy method for the analysis of 
esomeprazole. Hence, it is necessary to develop a rapid, 
accurate and validated RP-HPLC method for the 
determination of ESO in tablet dosage form. The method 
proved to be simple model since it does not contain a buffer 
system. This paper describes the development and validation 
of reliable, simple, robust, time and money saving reversed 
phase HPLC method, using PDA detection, for the estimation 
of ESO in tablet dosage forms. The developed method 
validated according to ICH guidelines 12. 
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Figure 1 Chemical structure of esomeprazole  
MATERIALS AND METHODS 
Instrumentation 
Liquid chromatographic system from Waters model no 784 
comprising of manual injector, water 515 binary pump for 
constant flow and constant pressure delivery and UV-Visible 
detector connected to software Data Ace for controlling the 
instrumentation as well as processing the generated data. 
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Weighing was done on a Digital Micro Balance (CX-265) 
manufactured by Citizen Scale (I) Pvt. Ltd.  
Reagents and chemicals  
Analytically pure sample of ESO was a generous gift from 
Glenmark Pharma Ltd., Baddi, along with their analytical 
reports. HPLC grade methanol and acetonitrile was obtained 
from Merck (India) limited. All other chemical used were of 
analytical grade. Triple distilled water was used for whole 
experiment was generated in house. Tablets ESOMZ 20, 20 
mg Dev Life Corporation Mumbai, India was purchased from 
local market.  
Chromatographic conditions 
The isocratic mobile phase consisted of methanol: 
acetonitrile (50:50 v/v), flowing through the column at a 
constant flow rate of 1.0 ml/ min.  The mobile phase was 
filtered through nylon 0.22 µm membrane filters and was 
degassed before use (30 min). A Thermo (C-18) column (5 
µm, 250mm x 4.60mm) was used as the stationary phase. By 
considering the chromatographic parameter, sensitivity and 
selectivity of method for drugs, 300 nm was selected as the 
detection wavelength for UV-Visible detector.  
Standard preparation  
Standard stock solution  
Accurately weighed 10 mg of ESO was transferred into 10 ml 
volumetric flask, dissolved in 5ml of methanol and volume 
was made up to 10ml with methanol to get concentration of 
solution 1000 g/ml (Stock-A), 5ml of stock-A was taken and 
diluted up to 50ml to get concentration of 100g/ml (Stock-
B). 
Working standard solution  
Working standard solutions were prepared by taking 
dilutions ranging from 5-25 g/ml for ESO. 
Sample preparation 
Commercial formulations ESO of ESOMZ 20mg was selected 
for analysis. Twenty tablets were taken and their average 
weight was determined. They are crushed to fine powder; 
amount equal to 10 mg of ESO was taken in 100-ml 
volumetric flask. The volume is made up to the mark by 
methanol and filtered by whatmann filter paper (no.41) and 
Then different concentration of solution were prepared by 
serial dilution technique, as per standard and each dilution 
was analyzed. 
RESULTS AND DISCUSSION 
Chromatography  
The mobile phase was chosen after several trials with 
methanol, isopropyl alcohol, acetonitrile, water and buffer 
solutions in various proportions and at different pH values. A 
mobile phase consisting of methanol: acetonitrile (50:50v/v) 
was selected to achieve maximum separation and sensitivity. 
Flow rates between 0.5 and 1.5 min were studied. A flow rate 
of 1 ml/min gave an optimal signal-to-noise ratio with a 
reasonable separation time. Using a reversed-phase C18 
column, the retention times for ESO was observed to be 
6.863 ± 0.3 min. Total time of analysis was less than 8 min. 
The maximum absorption of ESO was detected at 300nm and 
this wavelength was chosen for the analysis Fig. 2
 
 
(A) 
 
(B) 
Figure 2 Chromatograms of (A) Blank mobile phase (B) ESO (15μg/ml) as reference substances 
 
 
Jain et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(4):292-295 
 
ISSN: 2250-1177                                                                                  [294]                                                                                 CODEN (USA): JDDTAO 
System suitability  
System suitability parameters such as number of theoretical 
plates, HETP and peak tailing are determined. The results 
obtained are shown in Table 1. The number of theoretical 
plates for ESO was 45674. 
Table 1 Results of system suitability parameters 
Parameters Esomeprazole 
AUC* 1247.152 
No. of Theoretical Plates 45674 
Tailing Factor* 0.955 
Retention time* 6.863 
Calibration range (μg/ml)  5-25 
*Each value is the mean ± SD of six determinations 
Linearity  
The calibration curve was linear over the concentration 
range of 5-25 μg/ml for ESO. The linearity was represented 
by a linear regression equation as follows:  
Y (ESO) = 50.18 conc+8.069 (r2 = 0.999) 
Accuracy  
Method accuracy was performed by adding known amounts 
of ESO to the preanalysed tablet solution and then comparing 
the added concentration with the found concentration. Three 
levels of solutions were made which correspond to 80%, 
100% and 120% of the nominal analytical concentration 
(15μg/ml for ESO). Each level was made in triplicate table 2. 
The mean percentage recoveries obtained for ESO was 
99.78% and RSD was less than 1. 
Table 2 Results of recovery study 
% Level % Mean±SD* 
 Esomeprazole 
80% 100.22±0.244 
100% 99.95±0.170 
120% 99.78±0.170 
* Value of three replicate and three concentrations. 
Precision 
Repeatability  
Five dilutions in three replicates were analyzed in the same 
day for repeatability and results were found within 
acceptable limits (RSD < 2) as shown in table 3.  
Intermediate precision  
Five dilutions in three replicates were analyzed on two 
different days and by two analysts for day-to-day and 
analyst-to-analyst variations and results were found within 
acceptable limits (RSD < 2) as shown in table 3. 
Robustness  
As per ICH norms, small, but deliberate variations in 
concentration of the mobile phase were made to check the 
method’s capacity to remain unaffected. The ratio of mobile 
phase was change from, methanol: acetonitrile (50:50 % 
v/v), to (45: 55% V/V) and method is found robust as RSD is 
again found < 2.0 table 3. 
 
Table 3 Statistical data for precision and robustness 
Statistical parameter Esomeprazole 
Mean* S.D* R.S.D* 
Repeatability 99.74 0.028 0.028 
Intermediate Precision 
(I) (A day to day) 
99.27 0.041 0.383 
(II) Analyst to Analyst 99.62 0.99 0.99 
Robustness 99.45 0.065 0.546 
*Mean of 15 determinations (three replicates at five 
concentration level) 
Detection Limit and Quantitation Limit  
The LOD and LOQ of developed method were calculated 
based on the standard deviation of response and slope of the 
linearity curve table 4.  
Table 4 LOD and LOQ  
Name LOD (g/ml) LOQ (g/ml) 
Esomeprazole 0.100 0.314 
 
Analysis of tablets 
The assay value of drugs was close to 100, SD and % RSD are 
less than 2 indicate the no interference of excipients in the 
estimation of drug table 5. 
Table 5 Assay of tablet formulation 
S. No. Parameter Esomeprazole 
1. Mean 99.98 
2. S. D. 0.125 
3. % RSD 0.145 
Mean of nine determinations 
CONCLUSION 
The proposed HPLC method was validated as per the 
International Conference on Harmonisation (ICH) Q2B 
Guidelines, and was found to be applicable for routine 
quantitative analysis of ESO by HPLC in pharmaceutical 
dosage form. The results of linearity, precision, accuracy and 
specificity, were proved to be within the limits. The method 
provides selective quantification of ESO with no interference 
from other formulation excipients. The proposed method 
was highly reproducible, reliable, rapid, robust and specific. 
Therefore, a high percentage of recovery and the run time of 
less than seven minutes allow its application for the routine 
determination of ESO in the pharmaceutical dosage form. 
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